Tivic Health Systems Inc
TIVC0.858USD
+0.028+3.37%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.43MMarket Cap
LossP/E TTM
More Details of Tivic Health Systems Inc Company
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Tivic Health Systems Inc Info
Ticker SymbolTIVC
Company nameTivic Health Systems Inc
IPO dateNov 11, 2021
CEOErnst (Jennifer)
Number of employees7
Security typeOrdinary Share
Fiscal year-endNov 11
Address47685 Lakeview Blvd
CityFREMONT
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94538
Phone18882766888
Websitehttps://tivichealth.com/
Ticker SymbolTIVC
IPO dateNov 11, 2021
CEOErnst (Jennifer)
Company Executives of Tivic Health Systems Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+9444.00%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+9444.00%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Jan 11
Updated: Sun, Jan 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avenue Capital Group
4.02%
DRW Securities, LLC
2.14%
Marex Group plc
1.52%
Ernst (Jennifer)
1.29%
UBS Financial Services, Inc.
0.78%
Other
90.25%
Shareholders
Shareholders
Proportion
Avenue Capital Group
4.02%
DRW Securities, LLC
2.14%
Marex Group plc
1.52%
Ernst (Jennifer)
1.29%
UBS Financial Services, Inc.
0.78%
Other
90.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
4.51%
Investment Advisor/Hedge Fund
4.33%
Individual Investor
1.31%
Research Firm
0.06%
Other
89.79%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
22
224.75K
8.90%
+144.85K
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avenue Capital Group
101.64K
5.76%
+101.64K
--
Sep 30, 2025
DRW Securities, LLC
53.94K
3.05%
+53.94K
--
Sep 30, 2025
Marex Group plc
38.39K
2.17%
-890.00
-2.27%
Sep 30, 2025
Ernst (Jennifer)
32.69K
1.85%
+9.44K
+40.62%
Dec 18, 2025
UBS Financial Services, Inc.
801.00
0.05%
-4.85K
-85.83%
Sep 30, 2025
Geode Capital Management, L.L.C.
5.07K
0.29%
--
--
Nov 30, 2025
The Vanguard Group, Inc.
1.94K
0.11%
--
--
Nov 30, 2025
Citi Investment Research (US)
1.43K
0.08%
+1.43K
--
Sep 30, 2025
Wolf (Lisa G)
434.00
0.02%
+434.00
--
Dec 18, 2025
SBI Securities Co., Ltd.
16.00
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Date
Ex-dividend Date
Type
Ratio
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
